Interfering with mineralocorticoid receptor activation: The past, present, and future

F1000Prime Reports

Volumn 6, Issue , 2014, Pages

  Dorrance, Anne M ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANDROGEN RECEPTOR; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL L TYPE; DEOXYCORTICOSTERONE; EPLERENONE; FINERENONE; HYDROXYSTEROID DEHYDROGENASE; MESSENGER RNA; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; POTASSIUM; PROGESTERONE RECEPTOR; REACTIVE OXYGEN METABOLITE; SPIRONOLACTONE; STEROID RECEPTOR;

ADRENAL GLAND; ALDOSTERONE RELEASE; ESSENTIAL HYPERTENSION; GYNECOMASTIA; HEART FAILURE; HUMAN; IMPOTENCE; MENSTRUAL IRREGULARITY; NONHUMAN; REVIEW; TARGET CELL; VASCULAR SMOOTH MUSCLE; VASCULITIS; ZONA GLOMERULOSA;

EID: 84906974270     PISSN: 20517599     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P6-61     Document Type: Review

References (127)

1. Shen JZ, Young MJ: Corticosteroids, heart failure, and hypertension: a role for immune cells? Endocrinology 2012, 153:5692-700.
2. Funder JW: RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 2005, 93:121-5.
3. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-21.
4. Funder JW: Mineralocorticoid-receptor blockade, hypertension and heart failure. Nat Clin Pract Endocrinol Metab 2005, 1:4-5.
5. McGraw AP, McCurley A, Preston IR, Jaffe IZ: Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications. Curr Atheroscler Rep 2013, 15:340.
6. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H: Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994, 269:24316-20.
7. Hatakeyama H, Miyamori I, Takeda Y, Yamamoto H, Mabuchi H: The expression of steroidogenic enzyme genes in human vascular cells. Biochem Mol Biol Int 1996, 40:639-45.
8. Takeda Y, Miyamori I, Yoneda T, Iki K, Hatakeyama H, Blair IA, Hsieh FY, Takeda R: Production of aldosterone in isolated rat blood vessels. Hypertension 1995, 25:170-3.
9. Takeda Y, Miyamori I, Inaba S, Furukawa K, Hatakeyama H, Yoneda T, Mabuchi H, Takeda R: Vascular aldosterone in genetically hypertensive rats. Hypertension 1997, 29:45-8.
10. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, Swynghedauw B, Delcayre C: Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 1998, 273:4883-91.
11. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H: Cardiac aldosterone production in genetically hypertensive rats. Hypertension 2000, 36:495-500.
12. Ye P, Kenyon CJ, MacKenzie SM, Jong AS, Miller C, Gray GA, Wallace A, Ryding AS, Mullins JJ, McBride MW, Graham D, Fraser R, Connell, JMC, Davies E: The aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) genes are not expressed in the rat heart. Endocrinology 2005, 146:5287-93.
13. Briones AM, Nguyen Dinh Cat, Aurelie, Callera GE, Yogi A, Burger D, He Y, Corrêa JW, Gagnon AM, Gomez-Sanchez CE, Gomez-Sanchez EP, Sorisky A, Ooi TC, Ruzicka M, Burns KD, Touyz RM: Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 2012, 59:1069-78.
14. MacKenzie SM, Connell, John MC, Davies E: Non-adrenal synthesis of aldosterone: a reality check. Mol Cell Endocrinol 2012, 350:163-7.
15. MacKenzie SM, Huda SS, Sattar N, Fraser R, Connell, John MC, Davies E: Depot-specific steroidogenic gene transcription in human adipose tissue. Clin Endocrinol (Oxf) 2008, 69:848-54.
16. Williams GH: Aldosterone biosynthesis, regulation, and classical mechanism of action. Heart Fail Rev 2005, 10:7-13.
17. Namsolleck P, Unger T: Aldosterone synthase inhibitors in cardiovascular and renal diseases. Nephrol Dial Transplant 2014, 29(Suppl 1):i62-i68.
18. Gekle M, Bretschneider M, Meinel S, Ruhs S, Grossmann C: Rapid mineralocorticoid receptor trafficking. Steroids 2014, 81:103-8.
19. Funder JW: Why are mineralocorticoid receptors so non-selective? Curr Hypertens Rep 2007, 9:112-6.
20. Fuller PJ, Yao Y, Yang J, Young MJ: Mechanisms of ligand specificity of the mineralocorticoid receptor. J Endocrinol 2012, 213:15-24.
21. Odermatt A, Atanasov AG: Mineralocorticoid receptors: emerging complexity and functional diversity. Steroids 2009, 74:163-71.
22. Chapman K, Holmes M, Seckl J: 11b-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action. Physiol Rev 2013, 93:1139-206.
23. Lathe R, Kotelevtsev Y: Steroid signaling: ligand-binding promiscuity, molecular symmetry, and the need for gating. Steroids 2014, 82:14-22.
24. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-17.
25. Brown NJ: Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 2013, 9:459-69.
26. Corvol P, Michaud A, Menard J, Freifeld M, Mahoudeau J: Anti-androgenic effect of spirolactones: mechanism of action. Endocrinology 1975, 97:52-8.
27. Greenblatt DJ, Koch-Weser J: Gynecomastia and impotence: complications of spironolactone therapy. JAMA 1973, 223:82.
28. Stripp B, Taylor AA, Bartter FC, Gillette JR, Loriaux DL, Easley R, Menard RH: Effect of spironolactone on sex hormones in man. J Clin Endocrinol Metab 1975, 41:777-81.
29. Levitt JI: Spironolactone therapy and amenorrhea. JAMA 1970, 211:2014-5.
30. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, Corvol P, Menard J: Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987, 60:820-5.
31. Gasparo M de, Whitebread SE, Preiswerk G, Jeunemaître X, Corvol P, Ménard J: Antialdosterones: incidence and prevention of sexual side effects. J Steroid Biochem 1989, 32:223-7.
32. Garthwaite SM, McMahon EG: The evolution of aldosterone antagonists. Mol Cell Endocrinol 2004, 217:27-31.
33. Hu X, Li S, McMahon EG, Lala DS, Rudolph AE: Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone. Mini Rev Med Chem 2005, 5:709-18.
34. Ménard J: The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol 2004, 217:45-52.
35. Weinberger MH, Roniker B, Krause SL, Weiss RJ: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002, 15:709-16.
36. Parthasarathy HK, Ménard J, White WB, Young WF, Williams GH, Williams B, Ruilope LM, McInnes GT, Connell JM, MacDonald TM: A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens 2011, 29:980-90.
37. Lopez LM, Kaptein AA, Helmerhorst FM: Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2012, 2:CD006586.
38. Cook CS, Berry LM, Bible RH, Hribar JD, Hajdu E, Liu NW: Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab Dispos 2003, 31:1448-55.
39. Sadée W, Dagcioglu M, Riegelman S: Fluorometric microassay for spironolactone and its metabolites in biological fluids. J Pharm Sci 1972, 61:1126-9.
40. Derosa G, Bonaventura A, Bianchi L, Romano D, D'Angelo A, Fogari E, Maffioli P: Effects of canrenone in patients with metabolic syndrome. Expert Opin Pharmacother 2013, 14:2161-9.
41. Northcott CA, Fink GD, Garver H, Haywood JR, Laimon-Thomson EL, McClain JL, Pires PW, Rainey WE, Rigsby CS, Dorrance AM: The development of hypertension and hyper-aldosteronism in a rodent model of life-long obesity. Endocrinology 2012, 153:1764-73.
42. Young M, Funder J: Mineralocorticoid action and sodium-hydrogen exchange: studies in experimental cardiac fibrosis. Endocrinology 2003, 144:3848-51.
43. Armanini D, Sabbadin C, Donà G, Clari G, Bordin L: Aldosterone receptor blockers spironolactone and canrenone: two multi-valent drugs. Expert Opin Pharmacother 2014, 15:909-12.
44. Armanini D, Karbowiak I, Goi A, Mantero F, Funder JW: In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay. Clin Endocrinol (Oxf) 1985, 23:341-7.
45. Francavilla A, Di Leo A, Eagon PK, Polimeno L, Guglielmi F, Fanizza G, Barone M, Starzl TE: Effect of spironolactone and potassium canrenoate on cytosolic and nuclear androgen and estrogen receptors of rat liver. Gastroenterology 1987, 93:681-6.
46. Caprio M, Newfell BG, La Sala A, Baur W, Fabbri A, Rosano G, Mendelsohn ME, Jaffe IZ: Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 2008, 102:1359-67.
47. Rigsby CS, Ergul A, Portik Dobos V, Pollock DM, Dorrance AM: Effects of spironolactone on cerebral vessel structure in rats with sustained hypertension. Am J Hypertens 2011, 24:708-15.
48. Hatakeyama H, Inaba S, Takeda R, Miyamori I: 11beta-hydroxysteroid dehydrogenase in human vascular cells. Kidney Int 2000, 57:1352-7.
49. Hatakeyama H, Inaba S, Miyamori I: 11beta-hydroxysteroid dehydrogenase in cultured human vascular cells. Possible role in the development of hypertension. Hypertension 1999, 33:1179-84.
50. Brem AS, Bina RB, King TC, Morris DJ: Localization of 2 11beta-OH steroid dehydrogenase isoforms in aortic endothelial cells. Hypertension 1998, 31:459-62.
51. Gong R, Morris DJ, Brem AS: Variable expression of 11beta Hydroxysteroid dehydrogenase (11beta-HSD) isoforms in vascular endothelial cells. Steroids 2008, 73:1187-96.
52. Young MJ, Moussa L, Dilley R, Funder JW: Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation. Endocrinology 2003, 144:1121-5.
53. Wilson P, Morgan J, Funder JW, Fuller PJ, Young MJ: Mediators of mineralocorticoid receptor-induced profibrotic inflammatory responses in the heart. Clin Sci 2009, 116:731-9.
54. Rickard AJ, Young MJ: Corticosteroid receptors, macrophages and cardiovascular disease. J Mol Endocrinol 2009, 42:449-59.
55. Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ: Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 2009, 54:537-43.
56. Usher MG, Duan SZ, Ivaschenko CY, Frieler RA, Berger S, Schütz G, Lumeng CN, Mortensen RM: Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 2010, 120:3350-64.
57. Lim H, Müller N, Herold MJ, van den Brandt, Jens, Reichardt HM: Glucocorticoids exert opposing effects on macrophage function dependent on their concentration. Immunology 2007, 122:47-53.
58. Armanini D, Strasser T, Weber PC: Binding of agonists and antagonists to mineralocorticoid receptors in human peripheral mononuclear leucocytes. J Hypertens Suppl 1985, 3:S157-9.
59. Labuzek K, Liber S, Bułdak L, Krupej-Ke¸dzierska J, Machnik G, Bobrzyk M, Okopień B: Eplerenone mimics features of the alternative activation in macrophages obtained from patients with heart failure and healthy volunteers. Eur J Pharmacol 2014, 726C:96-108.
60. Łabuzek K, Liber S, Bułdak Ł, Machnik G, Liber J, Okopień B: Eplerenone promotes alternative activation in human monocyte-derived macrophages. Pharmacol Rep 2013, 65:226-34.
61. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG: Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007, 204:2449-60.
62. Amador CA, Barrientos V, Peña J, Herrada AA, González M, Valdés S, Carrasco L, Alzamora R, Figueroa F, Kalergis AM, Michea L: Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes. Hypertension 2014, 63:797-803.
63. van den Meiracker, Anton H, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F: Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens 2006, 24:2285-92.
64. Samuel J, Delcayre C: Heart failure: aldosterone antagonists are underused by clinicians. Nat Rev Cardiol 2010, 7:125-7.
65. McMurray, John JV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip, Gregory Y H, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012, 33:1787-847.
66. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW: 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009, 53:e1-e90.
67. Vaduganathan M, Fonarow GC, Gheorghiade M: Drug therapy to reduce early readmission risk in heart failure: ready for prime time? JACC Heart Fail 2013, 1:361-4.
68. Talatinian A, Chow SL, Heywood JT: Expanding role of mineralocorticoid receptor antagonists in the treatment of heart failure. Pharmacotherapy 2012, 32:827-37.
69. Kolkhof P, Borden SA: Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol 2012, 350:310-7.
70. Arhancet GB, Woodard SS, Dietz JD, Garland DJ, Wagner GM, Iyanar K, Collins JT, Blinn JR, Numann RE, Hu X, Huang H: Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines. J Med Chem 2010, 53:4300-4.
71. Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, Funder JW, Hu X: A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008, 51:742-8.
72. Kosaka H, Hirayama K, Yoda N, Sasaki K, Kitayama T, Kusaka H, Matsubara M: The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family. Eur J Pharmacol 2010, 635:49-55.
73. Matsui T, Takeuchi M, Yamagishi S: Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced glycation end product (AGE)-exposed fibroblasts via mineralocorticoid receptor antagonistic activity. Biochem Biophys Res Commun 2010, 396:566-70.
74. Bärfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Pérez S, Heckroth H, Nitsche A, Ergüden J, Gielen-Haertwig H, Schlemmer K, Mittendorf J, Paulsen H, Platzek J, Kolkhof P: Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 2012, 7:1385-403.
75. Pitt B, Filippatos G, Gheorghiade M, Kober L, Krum H, Ponikowski P, Nowack C, Kolkhof P, Kim S, Zannad F: Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail 2012, 14:668-75.
76. Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim S, Zannad F: Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 2013, 34:2453-63.
77. Bauersachs J: The ARTS of third-generation mineralocorticoid receptor antagonists: achieving cardiovascular benefit with minimized renal side effects? Eur Heart J 2013, 34:2426-8.
78. Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Bärfacker L, Eitner F, Albrecht-Küpper B, Schäfer S: Finerenone, a novel selective non-steroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 2014.
79. Cerny MA: Progress towards clinically useful aldosterone synthase inhibitors. Curr Top Med Chem 2013, 13:1385-401.
80. Bomback AS, Klemmer PJ: The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007, 3:486-92.
81. Nobakht N, Kamgar M, Rastogi A, Schrier RW: Limitations of angiotensin inhibition. Nat Rev Nephrol 2011, 7:356-9.
82. Mornet E, Dupont J, Vitek A, White PC: Characterization of two genes encoding human steroid 11 beta-hydroxylase (P-450(11) beta). J Biol Chem 1989, 264:20961-7.
83. Ménard J, Gonzalez M, Guyene T, Bissery A: Investigation of aldosterone-synthase inhibition in rats. J Hypertens 2006, 24: 1147-55.
84. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-Saadi N, Dechend R, Wellner M, Meiners S, Maser-Gluth C, Jeng AY, Webb RL, Luft FC, Muller DN: Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005, 111:3087-94.
85. Mulder P, Mellin V, Favre J, Vercauteren M, Remy-Jouet I, Monteil C, Richard V, Renet S, Henry JP, Jeng AY, Webb RL, Thuillez C: Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J 2008, 29:2171-9.
86. Lea WB, Kwak ES, Luther JM, Fowler SM, Wang Z, Ma J, Fogo AB, Brown NJ: Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int 2009, 75:936-44.
87. Hargovan M, Ferro A: Aldosterone synthase inhibitors in hypertension: current status and future possibilities. JRSM Cardiovasc Dis 2014, 3:2048004014522440.
88. Amar L, Azizi M, Menard J, Peyrard S, Watson C, Plouin P: Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patientswith primary aldosteronism. Hypertension 2010, 56:831-8.
89. Calhoun DA, White WB, Krum H, Guo W, Bermann G, Trapani A, Lefkowitz MP, Ménard J: Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation 2011, 124:1945-55.
90. Andersen K, Hartman D, Peppard T, Hermann D, van Ess P, Lefkowitz M, Trapani A: The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study. J Clin Hypertens (Greenwich) 2012, 14:580-7.
91. Karns AD, Bral JM, Hartman D, Peppard T, Schumacher C: Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension. J Clin Hypertens (Greenwich) 2013, 15:186-92.
92. Amar L, Azizi M, Menard J, Peyrard S, Plouin P: Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism. J Hypertens 2013, 31:624-9; discussion 629.
93. Bertagna X, Pivonello R, Fleseriu M, Zhang Y, Robinson P, Taylor A, Watson CE, Maldonado M, Hamrahian AH, Boscaro M, Biller, Beverly M K: LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from amulticenter, proof-of-concept study. J Clin Endocrinol Metab 2014, 99:1375-83.
94. Williams JS: Evolving research in nongenomic actions of aldosterone. Curr Opin Endocrinol Diabetes Obes 2013, 20:198-203.
95. Wendler A, Albrecht C, Wehling M: Nongenomic actions of aldosterone and progesterone revisited. Steroids 2012, 77:1002-6.
96. Grossmann C, Gekle M: New aspects of rapid aldosterone signaling. Mol Cell Endocrinol 2009, 308:53-62.
97. Dooley R, Harvey BJ, Thomas W: Non-genomic actions of aldosterone: from receptors and signals tomembrane targets. Mol Cell Endocrinol 2012, 350:223-34.
98. Christ M, Eisen C, Aktas J, Theisen K, Wehling M: The inositol-1,4,5-trisphosphate system is involved in rapid effects of aldosterone in human mononuclear leukocytes. J Clin Endocrinol Metab 1993, 77:1452-7.
99. Christ M, Meyer C, Sippel K, Wehling M: Rapid aldosterone signaling in vascular smooth muscle cells: involvement of phospholipase C, diacylglycerol and protein kinase C alpha. Biochem Biophys Res Commun 1995, 213:123-9.
100. Christ M, Günther A, Heck M, Schmidt BM, Falkenstein E, Wehling M: Aldosterone, not estradiol, is the physiological agonist for rapid increases in cAMP in vascular smooth muscle cells. Circulation 1999, 99:1485-91.
101. Wehling M, Neylon CB, Fullerton M, Bobik A, Funder JW: Nongenomic effects of aldosterone on intracellular Ca2+ in vascular smooth muscle cells. Circ Res 1995, 76:973-9.
102. Gekle M, Freudinger R, Mildenberger S, Schenk K, Marschitz I, Schramek H: Rapid activation of Na+/H+-exchange in MDCK cells by aldosterone involves MAP-kinase ERK1/2. Pflugers Arch 2001, 441:781-6.
103. McEneaney V, Dooley R, Harvey BJ, Thomas W: Protein kinase D stabilizes aldosterone-induced ERK1/2 MAP kinase activation in M1 renal cortical collecting duct cells to promote cell proliferation. J Steroid Biochem Mol Biol 2010, 118:18-28.
104. Callera GE, Montezano, Augusto C I, Yogi A, Tostes RC, He Y, Schiffrin EL, Touyz RM: c-Src-dependent nongenomic signaling responses to aldosterone are increased in vascular myocytes from spontaneously hypertensive rats. Hypertension 2005, 46:1032-8.
105. Callera GE, Touyz RM, Tostes RC, Yogi A, He Y, Malkinson S, Schiffrin EL: Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension 2005, 45:773-9.
106. Goto J, Otsuka F, Yamashita M, Suzuki J, Otani H, Takahashi H, Miyoshi T, Mimura Y, Ogura T, Makino H: Enhancement of aldosterone-induced catecholamine production by bone morphogenetic protein-4 through activating Rho and SAPK/JNK pathway in adrenomedullar cells. Am J Physiol Endocrinol Metab 2009, 296: E904-16.
107. Gros R, Ding Q, Liu B, Chorazyczewski J, Feldman RD: Aldosterone mediates its rapid effects in vascular endothelial cells through GPER activation. Am J Physiol Cell Physiol 2013, 304:C532-40.
108. Gros R, Ding Q, Davis M, Shaikh R, Liu B, Chorazyczewski J, Pickering JG, Feldman RD: Delineating the receptor mechanisms underlying the rapid vascular contractile effects of aldosterone and estradiol. Can J Physiol Pharmacol 2011, 89:655-63.
109. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, Parker MA, Tkachenko SE, Savchuck NP, Sklar LA, Oprea TI, Prossnitz ER: Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2006, 2:207-12.
110. Dennis MK, Burai R, Ramesh C, Petrie WK, Alcon SN, Nayak TK, Bologa CG, Leitao A, Brailoiu E, Deliu E, Dun NJ, Sklar LA, Hathaway HJ, Arterburn JB, Oprea TI, Prossnitz ER: In vivo effects of a GPR30 antagonist. Nat Chem Biol 2009, 5:421-7.
111. Lindsey SH, Cohen JA, Brosnihan KB, Gallagher PE, Chappell MC: Chronic treatment with the G protein-coupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2.Lewis rats. Endocrinology 2009, 150:3753-8.
112. Lindsey SH, Carver KA, Prossnitz ER, Chappell MC: Vasodilation in response to the GPR30 agonist G-1 is not different from estradiol in the mRen2.Lewis female rat. J Cardiovasc Pharmacol 2011, 57:598-603.
113. Toda N, Nakanishi S, Tanabe S: Aldosterone affects blood flow and vascular tone regulated by endothelium-derived NO: therapeutic implications. Br J Pharmacol 2013, 168:519-33.
114. Jaffe IZ, Jaisser F: Endothelial cell mineralocorticoid receptors: turning cardiovascular risk factors into cardiovascular dysfunction. Hypertension 2014, 63:915-7.
115. McCurley A, Jaffe IZ: Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol 2012, 350:256-65.
116. Heylen E, Huang A, Sun D, Kaley G: Nitric oxide-mediated dilation of arterioles to intraluminal administration of aldosterone. J Cardiovasc Pharmacol 2009, 54:535-42.
117. Weber KT, Brilla CG, Janicki JS, Reddy HK, Campbell SE: Myocardial fibrosis: role of ventricular systolic pressure, arterial hypertension, and circulating hormones. Basic Res Cardiol 1991, 86 (Suppl 3):25-31.
118. Campbell SE, Diaz-Arias AA, Weber KT: Fibrosis of the human heart and systemic organs in adrenal adenoma. Blood Press 1992, 1:149-56.
119. Brilla CG, Weber KT: Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992, 120:893-901.
120. Weber KT, Villarreal D: Aldosterone and antialdosterone therapy in congestive heart failure. Am J Cardiol 1993, 71:3A-11A.
121. Brilla CG, Matsubara LS, Weber KT: Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993, 25:563-75.
122. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC: High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994, 21:315-8.
123. Lim PO, Rodgers P, Cardale K, Watson AD, MacDonald TM: Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 1999, 353:40.
124. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello M, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F: A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006, 48:2293-300.
125. Fardella CE, Mosso L, Gómez-Sánchez C, Cortés P, Soto J, Gómez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J: Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000, 85:1863-7.
126. Connell, John MC, Fraser R, MacKenzie S, Davies E: Is altered adrenal steroid biosynthesis a key intermediate phenotype in hypertension? Hypertension 2003, 41:993-9.
127. Yagi S, Akaike M, Aihara K, Iwase T, Yoshida S, Sumitomo-Ueda Y, Ikeda Y, Ishikawa K, Matsumoto T, Sata M: High plasma aldosterone concentration is a novel risk factor of cognitive impairment in patients with hypertension. Hypertens Res 2011, 34:74-8.